These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31046497)

  • 1. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
    Dote S; Ito K; Itakura S; Yasu T; Hira D; Noda S; Yamada S; Kobayashi Y; Terada T
    Leuk Lymphoma; 2019 Dec; 60(12):2975-2981. PubMed ID: 31046497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash.
    Sugi T; Mita M; Yasu T; Kubo K; Kushi R; Hanai H; Ohara S; Uchida T; Inoue M; Hagihara M
    J Clin Pharm Ther; 2022 Apr; 47(4):477-482. PubMed ID: 34778985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.
    Sugi T; Nishigami Y; Saigo H; Hanai H; Takabatake K; Mita M; Ohara S; Ide S; Uchida T; Inoue M; Hagihara M
    Leuk Lymphoma; 2021 Jun; 62(6):1405-1410. PubMed ID: 33509006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
    Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
    Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective Analysis of Bortezomib or Lenalidomide for Very Elderly Patients with Newly Diagnosed Multiple Myeloma].
    Okayama Y; Takakuwa T; Otomaru I; Horiuchi M; Miura A; Araki T; Fujitani Y; Yamamura R
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):815-819. PubMed ID: 34139730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
    Sugi T; Mita M; Yasu T; Ohara S; Uchida T; Inoue M; Hagihara M
    J Clin Pharm Ther; 2021 Dec; 46(6):1792-1795. PubMed ID: 33960000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
    Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
    [No Abstract]   [Full Text] [Related]  

  • 10. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
    Teitelbaum A; Ba-Mancini A; Huang H; Henk HJ
    Oncologist; 2013; 18(1):37-45. PubMed ID: 23299776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
    Olszewski AJ; Barth PM; Reagan JL
    Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
    Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
    Front Immunol; 2018; 9():704. PubMed ID: 29706958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
    Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
    Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.
    Kuo AM; Hassoun H; Shah U; Gordon A; Hollmann TJ; Landau HJ; Lezcano C; Mailankody S; Tan CC; Lesokhin AM; Markova A
    Leuk Lymphoma; 2022 Sep; 63(9):2233-2237. PubMed ID: 35532206
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
    Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
    Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
    Buonomo M; Kabbur G; El Jurdi N; Giubellino A; Schultz B
    Dermatol Online J; 2021 Dec; 27(12):. PubMed ID: 35499443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
    Bici A; Pianko MJ; Nachar VR
    Leuk Lymphoma; 2023 Feb; 64(2):407-414. PubMed ID: 36308285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.